林 家聖
Breaking Down RAN1#120: How Delegates Can Efficiently Tackle the Proposal Overload and Uncover Key Insights
The Growing Complexity of 3GPP Proposal Reviews The volume of technical discussions and proposals at...
了解更多林 家聖
The Growing Complexity of 3GPP Proposal Reviews The volume of technical discussions and proposals at...
了解更多林 家聖
The 3GPP RAN2#129bis meeting marked a turning point in standardizing AI/ML-driven UE behavior. As 5G...
了解更多林 家聖
Executive Summary For 3GPP RAN1 delegates, RAN1_120bis presents a defining opportunity to shape Rele...
了解更多黃 致遠
跨技術領域審查機制—提升專利審查品質 智慧局內部實施「跨領域系統審查」機制,針對跨領域技術,由審委主動尋求其他技術領域審委的協助,以確保審查品質與技術精準度。 再審查加速審查AEPRe—加速專利獲准 ...
了解更多黃 致遠
美國專利商標局費用調整:新申請、延續案、RCE全數調漲 2025年,美國專利商標局(USPTO)將對專利相關費用進行調整,全面性增幅約7.5%,其中新申請費用提高 10%,延續案申請與 RCE(Req...
了解更多林 家聖
Executive Summary Hello everyone! I'm excited to share some insights into the upcoming RAN2#129 meet...
了解更多林 家聖
The Growing Complexity of 3GPP Proposal Reviews The volume of technical discussions and proposals at...
了解更多王 皓恬
大分子藥物的研發特性與專利挑戰 相較於小分子藥物,大分子藥物因研發週期長、結構複雜、不可預期性高,使其專利佈局面臨更大挑戰。具體來說,大分子藥物通常無法如傳統小分子藥物般可藉由鹽類、晶型或異構體等方式...
了解更多林 家聖
Background Since RAN#105, 3GPP has advanced 5G with AI/ML integration. The NR_AIML_air work item now...
了解更多世博科技顧問股份有限公司
世博國際專利商標事務所
Copyright © 2022 WISPRO. All Rights Reserved